PT  - JOURNAL ARTICLE
AU  - Robert Armbrust
AU  - Sara Alavi
AU  - Adak Pirmorady
AU  - Frank Chen
AU  - Nicoletta Colombo
AU  - Murat Gultekin
AU  - Charo Hierro
AU  - Birthe Lemley
AU  - Mansoor Raza Mirza
AU  - Esra Urkmez
AU  - Christina Fotopoulou
AU  - Jutta Vinzent
AU  - Antonio Gonzalez Martin
AU  - Andrea Krull
AU  - Judith Heepe
AU  - Mathias Rose
AU  - Jalid Sehouli
TI  - Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment
AID  - 10.1136/ijgc-2019-001070
DP  - 2020 Oct 01
TA  - International Journal of Gynecologic Cancer
PG  - 1603--1607
VI  - 30
IP  - 10
4099  - http://ijgc.bmj.com/content/30/10/1603.short
4100  - http://ijgc.bmj.com/content/30/10/1603.full
SO  - Int J Gynecol Cancer2020 Oct 01; 30
AB  - Background Patients’ reported outcomes and their perspectives around their therapeutic management is a field of continuously increasing relevance in gynecological oncology. We report the results of the Berlin dialog on seven patient-reported parameters and outcomes concerning chemotherapy and maintenance treatment in patients with gynecological cancer.Methods Key opinion leaders in gynecological oncology from different European counties and representatives of leading patients’ advocate groups in Berlin held a consensus meeting in Berlin on April 6, 2019. Seven topics of interest were identified in advance around quality of life, iatrogenic toxicity, treatment decision-making processes, sexuality, participation in clinical trials, second opinion, and long-term survivors with the the following standard operating procedure for processing and discussion: (1) agreement on its relevance; (2) literature review, and (3) discussion and consensus statements.Results All main topics reached a consensus approval. The defined statements emphasized the importance of patients’ role in incorporating and establishing quality of life as an outcome parameter in clinical trials. Furthermore, discussants raised the importance of identifying new tools for reflecting patient-reported iatrogenic toxicity as well as emphasizing patients’ rights in providing personal information, access to second opinion in the decision-making process, and their participation in clinical trials.Conclusion The results of this round table meeting could help redefine perspectives on the discussed topics and the importance for therapeutic management as well as for trial designs.